AbbVie Inc
ABBVHealthcare|Drug Manufacturers - General|USA
$248.08
-1.83 (-0.73%)
DCF (FCF)
$102.04
Earnings Power
$55.26
Upcoming Data Readouts (96)
Sep 2026
Est. completion
P1Healthy Volunteer
A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants
NCT06953934n=8
Sep 2026
Est. completion
Crohn's Disease
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
NCT07421258n=2,000
Oct 2026
Est. completion
Oct 2026
Est. completion
P2Endometrial Cancer
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT03832361n=50
Oct 2026
Est. completion
P1Obesity
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
NCT07291232n=48
Nov 2026
Est. completion
Acute Myeloid Leukemia
A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
NCT06058741n=150
Nov 2026
Est. completion
P2Hepatocellular Carcinoma
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT05822752n=130
Nov 2026
Est. completion
P2High Grade Ovarian Cancer
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685n=125
Dec 2026
Est. completion
P2P3AMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921n=671
Dec 2026
Est. completion
Ulcerative Colitis
An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)
NCT06838845n=80
Dec 2026
Est. completion
Diabetic Macular Edema
Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant
NCT05978622n=236
Dec 2026
Est. completion
P3Hidradenitis Suppurativa
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228n=1,400
Dec 2026
Est. completion
P1Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
NCT06672705n=26
Dec 2026
Est. completion
P1Myeloproliferative Neoplasm
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
NCT04041050n=85
Jan 2027
Est. completion
P1Myelodysplastic Syndromes (MDS)
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
NCT02942290n=129
Jan 2027
Est. completion
Jan 2027
Est. completion
P1Healthy Volunteer
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
NCT07514260n=24
Feb 2027
Est. completion
P1Multiple Myeloma
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516n=60
Feb 2027
Est. completion
P2Rheumatoid Arthritis
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446n=180
Feb 2027
Est. completion
P2Lung Non-Small Cell Carcinoma
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
NCT07323641n=60
Awaiting Results (22)
Trials past primary completion date but still active — data readout may be imminent.
Aug 2026
P2
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT04514653Aug 2026
P3
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
NCT07032597Jul 2026
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
NCT06125795Jun 2026
A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
NCT04159779Jun 2026
P2
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550May 2026
P1
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
NCT06034470Mar 2026
P4
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT05144243Mar 2026
P1
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03893955Dec 2025
P1P2
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
NCT05782127